Remarkably similar CTLA-4 binding properties of therapeutic ipilimumab and tremelimumab antibodies

Monoclonal antibody based immune checkpoint blockade therapies have achieved clinical successes in management of malignant tumors. As the first monoclonal antibody targeting immune checkpoint molecules entered into clinics, the molecular basis of ipilimumab-based anti-CTLA-4 blockade has not yet bee...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Mengnan, Chai, Yan, Qi, Jianxun, Zhang, Catherine W.H., Tong, Zhou, Shi, Yi, Yan, Jinghua, Tan, Shuguang, Gao, George F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620161/
https://www.ncbi.nlm.nih.gov/pubmed/28978021
http://dx.doi.org/10.18632/oncotarget.18004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5620161/
https://www.ncbi.nlm.nih.gov/pubmed/28978021
http://dx.doi.org/10.18632/oncotarget.18004

Ejemplares similares